AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaTechnology, Industry, AgricultureHumanitiesInformation ScienceNamed GroupsHealth CareGeographicals
IntronsPolyethylene GlycolsRibavirinInterferon-alphaHepatitis C, ChronicAntiviral AgentsRecombinant ProteinsDrug Therapy, CombinationHepacivirusRNA, ViralGenotypeViral LoadHepatitis D, ChronicTreatment OutcomeRNA SplicingAlanine TransaminaseLiver CirrhosisHepatitis B, ChronicBase SequenceHepatitis CHepatitis B e AntigensExonsMolecular Sequence DataDrug Administration ScheduleLamivudineRetreatmentUridine MonophosphateSpliceosomesInjections, SubcutaneousRNA Splice SitesRNA PrecursorsEvolution, MolecularInterleukinsRecurrenceAmino Acid SequenceHepatitis B Surface AntigensLithuaniaUncertaintyPhylogenyCloning, MolecularThrombocytopeniaInterferonsHepatitis B virusTreatment FailureQuality-Adjusted Life YearsOligopeptidesNucleic Acid ConformationAlternative SplicingHepatitis C AntibodiesDouble-Blind MethodGenesSequence Homology, Nucleic AcidCost-Benefit AnalysisMulticenter Studies as TopicAnemiaDose-Response Relationship, DrugMarkov ChainsOrganophosphonatesBiopsySequence AlignmentSerine Proteinase InhibitorsProspective StudiesDisease ProgressionTime FactorsLogistic ModelsDNA, ViralAdenineNeutropeniaRNA, MessengerRNA, Small NuclearSequence Analysis, DNAConserved SequenceRNA, CatalyticLiver TransplantationEuglena gracilisRNA, FungalTranscription, GeneticDrug ToleranceRestriction MappingSequence Homology, Amino AcidDNAOpen Reading FramesRetrospective StudiesLiverBiological EvolutionModels, GeneticDNA, ComplementaryTrans-SplicingHIV InfectionsBiological MarkersGenes, FungalEuropean Continental Ancestry GroupChromosome MappingViral Nonstructural ProteinsGenomeGenes, PlantGenomic LibrarySpecies SpecificityPolymerase Chain ReactionChlorophyta
Alfa-2b and ribavirinRibavirinBeta-1aDiscontinueHepatitisIntoleranceDose
Alfa-2b and ribavirin3
  • A shorter course of therapy over 12 weeks with peginterferon alfa-2b and ribavirin is aseffective as a 24-week course for patients with HCV genotype 2 or 3 who have a responseto treatment at 4 weeks. (healthdrugpdf.com)
  • In the studies, the addition of VICTRELIS to peginterferon alfa-2b and ribavirin (PR) significantly improved sustained virologic response (SVR)1 - the goal of treatment - for adult patients who failed previous treatment (treatment-failure) and those who were new to treatment (treatment-naïve) for chronic hepatitis C virus (HCV) genotype 1, compared to standard therapy (PR) alone. (natap.org)
  • The HCV RESPOND-2 and HCV SPRINT-2 studies each evaluated two treatment strategies with VICTRELIS added to PEGINTRON (peginterferon alfa-2b) and ribavirin (PR) to assess the ability of VICTRELIS to improve SVR rates and potentially shorten overall treatment duration compared to the use of PR alone for 48 weeks, which is the current standard duration of therapy. (natap.org)
Ribavirin4
  • the A total of 283 patients were randomly assigned to a standard 24-week regimen of Department of Internal Medicine, Hospi- peginterferon alfa-2b at a dose of 1.0 µg per kilogram weekly plus ribavirin at a dose of tal Venosa, Venosa (V.C. (healthdrugpdf.com)
  • The best way to use Peg- Intron in this indication is in combination with ribavirin. (alldrugs.co.il)
  • Interferon monotherapy including Peg-Intron is indicated mainly in case of intolerance or contraindication to ribavirin. (alldrugs.co.il)
  • Primary results: Adding VICTRELIS significantly increased SVR compared to control The HCV RESPOND-2 study was conducted at U.S. and international sites, and included 403 adult patients who had failed prior therapy, including patients who relapsed or were non-responders to prior treatment with peginterferon and ribavirin. (natap.org)
Beta-1a1
  • Therefore, peginterferon beta-1a was not considered to have a significant risk on impacting the pharmacokinetics of concomitantly administered medications. (gpimedical.com)
Discontinue1
  • 12 g/dL after 4 weeks on a reduced dose, the patient should discontinue combination REBETOL/INTRON A therapy. (linkedlifedata.com)
Hepatitis1
  • Peg- Intron is indicated for the treatment of adult patients with histologically proven chronic hepatitis C who have elevated transaminases without liver decompensation and who are positive for serum HCV-RNA or anti-HCV including naive patients with clinically stable HIV coinfection. (alldrugs.co.il)
Intolerance1
  • If intolerance persists after dose adjustment, REBETOL/INTRON A therapy should be discontinued. (linkedlifedata.com)
Dose1
  • Dose Modifications: If severe adverse reactions or laboratory abnormalities develop during combination REBETOL/INTRON A therapy the dose should be modified, or discontinued if appropriate, until the adverse reactions abate. (linkedlifedata.com)